查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1857532

癌症基因治療市場按載體類型、治療類型、適應症、分期和最終用戶分類－2025-2032年全球預測

Cancer Gene Therapy Market by Vector Type, Therapy Type, Indication, Stage, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症基因治療市場規模將達到 118.1 億美元，複合年成長率為 19.94%。

主要市場統計數據
基準年 2024 27.5億美元
預計年份：2025年 33億美元
預測年份：2032年 118.1億美元
複合年成長率 (%) 19.94%

透過整合科學進步、遞送創新和切實可行的轉化策略，加速臨床可行的癌症基因療法的出現。

癌症基因治療正處於曲折點，數十年的基礎科學研究正與實際臨床應用和工業化生產融合。近年來，載體工程、遞送方式和分子標靶的進步，已使許多概念從實驗室原理驗證階段邁向人體試驗階段，並在某些情況下最終應用於臨床。同時，基因組分析、患者分層和伴隨診斷技術的改進，使得治療構建體能夠更精準地與生物學定義的特定人群相匹配，從而提高臨床效用的可能性，並為研發優先級的確定提供依據。

新的技術突破、監管調整和不斷發展的商業模式正在重塑治療方法的設計、生產和患者獲取途徑。

近年來，癌症基因治療領域發生了變革性的變化，這主要源於技術、監管和商業動態的交匯，這些因素顯著改變了計畫的風險狀況和市場准入的考慮。在技​​術方面，載體設計的改進，包括最佳化精神趨向性和降低免疫抗原性，以及非病毒遞送平台（例如脂質奈米顆粒）的創新，正在拓展可適應症和患者群體的範圍。同時，生產技術的規模化生產也日趨成熟可靠，從而能夠生產出更高品質、更高產量且分析控制更穩定的載體。

評估美國關稅政策變化對原料採購、供應鏈韌性和跨境臨床營運的營運和策略影響

影響跨境貿易的政策介入措施，例如關稅調整及相關海關措施，正開始對生技藥品和先進治療材料的採購、供應鏈發展產生影響。關稅結構的變化可能會增加進口原料的成本，例如特殊脂質、質體DNA生產試劑、病毒載體原料和一次性生產組件。這些增加的投入成本可能轉化為早期研發公司和受託製造廠商營運預算的增加，進而影響供應商整合、近岸採購和垂直整合等方面的決策。

臨床和商業細分市場的進一步分類揭示了載體選擇、治療方式、適應症複雜性、研發階段和最終用戶如何影響策略重點。

在一個細緻的細分框架闡明了載體類型、治療方法、適應症、研發階段和最終用戶等不同維度下，臨床前景和商業性可行性的交匯點。按載體類型分析，非病毒載體和病毒載體之間的差異決定了研發重點。非病毒載體包括脂質奈米顆粒、物理方法和聚合物奈米顆粒，其優點在於生產規模化和降低長期免疫抗原性風險。另一方面，病毒載體包括腺結合病毒、腺病毒、慢病毒和逆轉錄病毒平台，其優勢在於基因改造表達持久且可進行細胞特異性遞送，但需要專門的生產過程和安全性監測。此外，治療方法類型區分了體外和體內方法。體外方法利用自體或異體細胞工程工作流程，而體內方法則強調直接向組織進行全身性或局部給藥。

美洲、歐洲、中東和非洲以及亞太地區的競爭格局和病患准入情況將塑造差異化的研發和商業化策略。

區域動態至關重要，因為不同地區的法律規範、報銷環境、生產能力和患者獲取模式存在顯著差異。在美洲，成熟的監管管道、完善的商業性報銷機制和專注的生產生態系統支持加速臨床開發和商業化，但開發需要強力的衛生經濟學證據和支付方的積極參與。相反，歐洲、中東和非洲的情況則截然不同。儘管歐盟各司法管轄區提供協調一致的監管機制，但在報銷時間表和衛生技術評估預期方面仍存在差異。同時，中東和非洲的某些市場為建立策略夥伴關係關係以擴大患者獲取途徑提供了機會，但這需要製定個人化的監管和分銷策略。

整合平台差異化、生產規模和合作夥伴關係模式的企業策略將決定從臨床前景到商業性影響的進程。

公司層面的癌症基因治療發展軌跡受三個相互依存的因素驅動：科學研究平台深度、生產和規模化能力，以及在夥伴關係與許可方面的策略姿態。擁有專有載體工程和遞送平台的公司可以獲得差異化的臨床優勢，但將這些優勢轉化為臨床驗證需要透過穩健的臨床前模型和最佳化的CMC（化學、製造和控制）管道來謹慎地降低風險。同時，那些確保可靠生產能力的公司——無論是內部投資還是長期製造外包夥伴關係——都能降低執行風險，並確保關鍵測試和商業化上市的按時完成。因此，生產規模和品管方面的專業知識往往是至關重要的差異化因素。

生物製藥領導者可採取切實可行的策略步驟，以降低技術風險、加強供應鏈並協調與監管機構和支付方的關係，從而加快產品上市。

產業領導者應採取多管齊下的行動計劃，同時應對技術風險、供應鏈脆弱性、監管複雜性和支付方參與等問題。首先，應儘早優先選擇載體和遞送方式，並設立明確的決策節點，充分考慮可轉化性、可生產性和免疫抗原性。其次，應投資於靈活的生產策略，包括與合格的製造外包合作、盡可能就近採購以及建立應急能力以降低關稅和物流風險。這些措施將提高營運韌性，並加快成功專案的規模化推廣。

透明且可重複的研究途徑，結合一手專家訪談、二手科學綜合分析和質性檢驗，能夠得出可靠的結論。

本執行摘要的研究整合了第一手和第二手研究，以確保結論的平衡性和可重複性。第一手資料包括與臨床研究人員、生產專家、監管顧問和商業行業領導者進行的結構化訪談和諮詢，以了解實際營運限制、臨床設計偏好和支付方觀點。這些討論指導了對載體類型、給藥方法和臨床策略之間技術權衡的解讀，並有助於檢驗在生產規模化和合作活動中觀察到的趨勢。

整合臨床、技術、監管和商業性因素，幫助相關人員了解不斷發展的基因治療腫瘤生態系統。

總而言之，癌症基因療法正從以探索為主的領域轉向以轉化準確性、生產準備度和商業性敏銳度為成功標準的關鍵領域轉變。載體和遞送技術的創新正在拓展治療範圍，而臨床和監管方面的經驗則不斷完善專案設計和病患選擇。同時，供應鏈的考量和政策的轉變正在影響營運決策，迫使企業將採購、生產和物流與策略發展計畫相協調。因此，研發、生產、監管和商業團隊之間的跨部門整合對於降低研發管線風險和加速患者獲得治療至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 一種基於 CRISPR 的多重基因編輯策略，用於提高 CAR-T 細胞在固體癌治療中的持久性
  • 用於體內標靶遞送治療基因至腫瘤組織的奈米結構脂質奈米顆粒載體
  • 開發表達免疫調節細胞激素的溶瘤病毒載體以增強腫瘤清除率
  • 將人工智慧驅動的生物資訊學應用於基因治療疫苗設計中的個人化新抗原識別
  • 自動化封閉式生產平台的出現將加速病毒基因治療載體的GMP生產
  • 生物技術創新者與合約研發生產機構（CDMO）的策略聯盟簡化了癌症基因療法的臨床應用
  • 擴大監管框架，以支持新型基因療法腫瘤治療的加速核准管道
  • 多重鹼基編輯技術在固體癌原位矯正致癌點突變的進展
  • 透過開發結合基因療法和免疫查核點抑制劑的多模態聯合治療來克服腫瘤抗藥性機制

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按載體類型分類的癌症基因治療市場

  • 非病毒載體
    • 脂質奈米顆粒
    • 物理方法
    • 聚合物奈米粒子
  • 病毒載體
    • 腺相關
    • 腺病毒
    • 慢病毒
    • 逆轉錄病毒

第9章 癌症基因治療市場（依治療類型分類）

  • 體外
  • 體內

第10章 依適應症分類的癌症基因治療市場

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 攝護腺癌

第11章 癌症基因治療市場（按階段分類）

  • 實驗室測試
    • 階段
    • 第二階段
    • 第三階段
  • 商業的
  • 臨床前試驗

第12章 依最終用戶分類的癌症基因治療市場

  • 醫院診所
  • 腫瘤中心
  • 研究所

第13章 各地區癌症基因治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 癌症基因治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國癌症基因治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Gilead Sciences, Inc.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • bluebird bio, Inc.
    • Adaptimmune Therapeutics plc
    • Cellectis SA
    • uniQure NV
    • Transgene SA
    • Sorrento Therapeutics, Inc.
Product Code: MRR-B1685377A6FA

The Cancer Gene Therapy Market is projected to grow by USD 11.81 billion at a CAGR of 19.94% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.75 billion
Estimated Year [2025] USD 3.30 billion
Forecast Year [2032] USD 11.81 billion
CAGR (%) 19.94%

Catalyzing the emergence of clinically viable cancer gene therapies through integrated scientific advances, delivery innovations, and pragmatic translational strategies

Cancer gene therapy sits at an inflection point where decades of foundational science are converging with pragmatic clinical execution and industrial-scale manufacturing. Over recent years, advances in vector engineering, delivery modalities, and molecular targeting have transitioned many concepts from laboratory proof-of-principle to human testing, and in selected cases to clinical adoption. Simultaneously, improvements in genomic profiling, patient stratification, and companion diagnostics are enabling more precise matching of therapeutic constructs to biologically defined populations, thereby improving the probability of clinical benefit and informing development prioritization.

Consequently, stakeholders across research, development, manufacturing, and commercialization must approach gene therapy with a dual lens: one that appreciates the unique scientific demands of nucleic acid delivery and one that anticipates regulatory, reimbursement, and operational realities. As a result, strategic planning today requires integrated thinking about vector selection, manufacturing capacity, clinical trial design, and payer engagement. By aligning translational science with practical implementation pathways, organizations can shorten the path from target validation to patient access while managing technical risk and capital deployment.

Emerging technological breakthroughs, regulatory recalibrations, and evolving commercial models are reshaping therapeutic design, manufacturing, and patient access pathways

Recent transformative shifts in the cancer gene therapy landscape are driven by intersecting technological, regulatory, and commercial dynamics that materially alter program risk profiles and go-to-market calculus. On the technology front, improvements in vector design, including optimized tropism and reduced immunogenicity, as well as innovations in nonviral delivery platforms such as lipid nanoparticles, have expanded the range of feasible indications and patient populations. At the same time, manufacturing technologies are scaling more reliably, enabling higher-quality vectors at improved yields and with more consistent analytical control, which reduces batch variability and supports multi-site clinical development.

From a regulatory and policy perspective, agencies are refining guidance to better address the unique safety and quality considerations of gene therapies, while payers and health technology assessment bodies are experimenting with value-based contracting and outcomes-linked reimbursement. Collectively, these shifts are lowering certain barriers to entry and increasing the strategic value of partnerships between small innovators and established manufacturers. Consequently, organizations that can combine deep translational expertise with robust manufacturing partnerships and proactive payer engagement will be best positioned to convert scientific promise into sustainable clinical impact.

Assessing the operational and strategic implications of United States tariff policy changes on raw material sourcing, supply chain resilience, and cross-border clinical operations

Policy interventions affecting cross-border trade, including tariff revisions and related customs measures, have begun to influence procurement, sourcing, and supply chain architecture for biologics and advanced therapy materials. Changes in tariff structures can increase the cost of imported raw materials such as specialty lipids, plasmid DNA production reagents, viral vector inputs, and single-use manufacturing components. These incremental input costs translate into higher operational budgets for both early-stage developers and contract manufacturing organizations, which in turn may affect decisions about supplier consolidation, near-sourcing, or vertical integration.

Moreover, tariffs exert secondary effects on logistics and inventory strategies. To mitigate exposure to unpredictable policy shifts, companies are increasingly evaluating dual-sourcing strategies, regionalized inventories, and investments in local manufacturing capability. Consequently, clinical programs with geographically distributed trial sites must balance the desire for global patient enrollment against the complexity and cost of cross-border product shipments and import/export compliance. Over time, these structural responses can reshape partnership models and influence where organizations choose to site critical manufacturing and fill-finish operations, thereby altering the economics and speed of clinical and commercial deployment.

Disaggregated clinical and commercial segmentation reveals how vector choice, therapeutic modality, indication complexity, development stage, and end users shape strategic priorities

A nuanced segmentation framework clarifies where clinical promise intersects with commercial practicality across vector modalities, therapeutic approaches, indications, development stages, and end users. When analyzed by vector type, distinctions between nonviral and viral vectors shape R&D priorities: nonviral vectors encompass lipid nanoparticles, physical methods, and polymeric nanoparticles, offering advantages in manufacturing scalability and reduced long-term immunogenicity concerns, while viral vectors include adeno-associated, adenoviral, lentiviral, and retroviral platforms that provide durable transgene expression and cell-specific delivery advantages but demand specialized manufacturing and safety monitoring. Complementing this, therapy type differentiates ex vivo and in vivo approaches, with ex vivo modalities leveraging autologous or allogeneic cell manipulation workflows and in vivo strategies emphasizing direct systemic or localized delivery to tissues.

Indication segmentation further refines clinical strategy. Hematological cancers, including leukemia, lymphoma, and myeloma, have been fertile ground for adoptive cell therapies and targeted gene modifications because of accessible cell sources and well-characterized biomarkers, whereas solid tumors such as breast cancer, colorectal cancer, lung cancer, and prostate cancer present delivery barriers and immunosuppressive microenvironments that necessitate novel targeting and combination approaches. Stage segmentation is equally consequential: preclinical work informs vector selection and nonclinical safety profiling, clinical trials span Phase I, Phase II, and Phase III with escalating complexity in endpoint selection and operational scale, and commercial programs require robust quality systems and distribution networks. Finally, end users such as hospitals and clinics, specialized oncology centers, and research laboratories impose distinct demands on product presentation, cold chain logistics, training requirements, and reimbursement interactions. Taken together, these interlocking segmentation dimensions determine technology risk, capital intensity, partner selection, and commercialization pathways.

Regional competitive contours and patient access narratives across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated development and commercialization strategies

Regional dynamics matter because regulatory frameworks, reimbursement environments, manufacturing capacity, and patient access models differ substantially across geographies. In the Americas, mature regulatory pathways, established commercial reimbursement mechanisms, and concentrated manufacturing ecosystems support accelerated clinical development and commercialization, but market access requires robust health economic evidence and payer engagement. Conversely, Europe, Middle East & Africa exhibit heterogeneity: EU jurisdictions offer coordinated regulatory mechanisms yet diverge on reimbursement timelines and HTA expectations, while certain markets in the Middle East and Africa present opportunities for strategic partnerships to expand access but necessitate tailored regulatory and distribution strategies.

In the Asia-Pacific region, rapid investments in local manufacturing, rising clinical trial activity, and growing government support for biotechnology create fertile conditions for clinical translation and regional supply chains. However, differences in regulatory harmonization, patient population genetics, and healthcare infrastructure mean that go-to-market plans must be regionally adapted. Therefore, organizations should prioritize regulatory intelligence, localized clinical pathways, and supply chain resiliency when establishing presence across the Americas, Europe, Middle East & Africa, and Asia-Pacific to ensure that development timelines and commercial rollouts remain aligned with regional realities.

Company strategies that integrate platform differentiation, manufacturing scale, and collaborative partnership models determine who advances from clinical promise to commercial impact

Company-level trajectories in cancer gene therapy are driven by three interdependent factors: the depth of scientific platform, manufacturing and scale capabilities, and the strategic posture toward partnerships and licensing. Organizations with proprietary vector engineering or delivery platforms can capture differentiated clinical advantages, but translating those advantages into clinical proof requires careful de-risking through robust preclinical models and optimized CMC pathways. In parallel, companies that secure reliable manufacturing capacity-either through in-house investment or long-term contract manufacturing partnerships-reduce execution risk and maintain timelines for pivotal studies and commercial launches. Thus, manufacturing footprint and quality control expertise often become decisive differentiators.

Furthermore, firms adopting collaborative business models that combine early-stage innovation with established commercial or manufacturing partners tend to accelerate patient access while preserving upside through milestone and royalty structures. Strategic alliances that align clinical development plans, regulatory submission strategies, and market access evidence generation help firms navigate HTA negotiations and payer dialogues. Ultimately, the most successful companies will be those that integrate scientific differentiation with pragmatic manufacturing strategies and thoughtful commercial partnerships to move therapies from proof-of-concept to reliable patient delivery.

Actionable strategic measures for biopharma leaders to reduce technical risk, reinforce supply chains, and align regulatory and payer engagement for accelerated access

Industry leaders should adopt a multi-pronged action plan that addresses technical risk, supply chain fragility, regulatory complexity, and payer engagement concurrently. First, prioritize vector and delivery selection early with clear decision gates that weigh translatability, manufacturability, and immunogenicity; this reduces downstream attrition and focuses capital on the most viable constructs. Second, invest in flexible manufacturing strategies that include qualified contract manufacturing partnerships, near-sourcing where feasible, and contingency capacity to mitigate tariff and logistics risks. These moves improve operational resilience and accelerate the ability to scale successful programs.

Third, engage regulators and payers proactively to align on evidentiary needs, safety monitoring frameworks, and value demonstration pathways; early alignment reduces the risk of late-stage surprises and facilitates smoother reimbursement discussions. Fourth, design clinical programs that incorporate robust biomarker strategies and adaptive elements to enhance patient selection and endpoint sensitivity. Finally, pursue partnerships that augment internal capabilities-whether for manufacturing, regulatory expertise, or commercial infrastructure-so that scientific innovators can leverage complementary strengths and accelerate patient access. Taken together, these actions create a pragmatic roadmap for converting scientific innovation into durable clinical and commercial outcomes.

A transparent and reproducible research approach combining primary expert interviews, secondary scientific synthesis, and qualitative validation to support robust conclusions

The research underpinning this executive summary integrated primary stakeholder engagement with systematic secondary synthesis to ensure balanced, reproducible conclusions. Primary inputs included structured interviews and consultations with clinical investigators, manufacturing experts, regulatory advisors, and commercial leaders to capture real-world operational constraints, clinical design preferences, and payer perspectives. These discussions informed the interpretation of technical tradeoffs between vector types, delivery methods, and clinical strategies, and helped validate observed trends in manufacturing scale-up and partnership activity.

Secondary research involved a comprehensive review of peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to map technological developments and regulatory evolution. Throughout the process, qualitative validation steps such as cross-checking assertions with multiple independent experts and reconciling divergent viewpoints were applied to reduce bias. Finally, findings were synthesized to highlight strategic implications rather than to produce proprietary market metrics, ensuring the analysis emphasizes actionable intelligence for decision-makers while remaining transparent about methodology and evidence sources.

Synthesis of clinical, technical, regulatory, and commercial considerations to guide stakeholders through the evolving gene therapy oncology ecosystem

In summary, cancer gene therapy is transitioning from a predominantly exploratory field to one in which translational fidelity, manufacturing readiness, and commercial foresight jointly determine success. Vector and delivery innovations broaden the therapeutic scope, while clinical and regulatory learnings refine program design and patient selection. Meanwhile, supply chain considerations and policy shifts influence operational choices, compelling organizations to align sourcing, manufacturing, and logistics with strategic development plans. As a result, cross-functional integration across R&D, manufacturing, regulatory, and commercial teams is essential to de-risk pipelines and accelerate patient access.

Looking ahead, the ecosystem will reward entities that combine rigorous translational science with disciplined program management and strategic partnerships. By focusing on modular manufacturing investments, proactive regulatory engagement, and evidence generation that resonates with payers, developers can improve the predictability of development pathways and enhance the likelihood of sustainable clinical impact. Ultimately, careful orchestration of technical, operational, and commercial activities will determine which therapies achieve broad patient adoption and which programs stall despite promising biology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. CRISPR-based multiplexed gene editing strategies refining CAR-T cell persistence in solid tumor treatments
  • 5.2. Nanoformulated lipid nanoparticle carriers enabling in vivo targeted delivery of therapeutic genes to tumor tissue
  • 5.3. Development of oncolytic viral vectors expressing immunomodulatory cytokines to enhance tumor eradication
  • 5.4. Integration of AI-driven bioinformatics for personalized neoantigen identification in gene therapy vaccine design
  • 5.5. Emergence of automated closed-system manufacturing platforms accelerating GMP production of viral gene therapy vectors
  • 5.6. Strategic alliances between biotech innovators and CDMOs streamlining clinical translation of cancer gene therapies
  • 5.7. Expanding regulatory frameworks supporting expedited approval pathways for novel gene therapy oncology treatments
  • 5.8. Advances in multiplexed base editing techniques to correct oncogenic point mutations in solid tumor cells in situ
  • 5.9. Deploying multi-modal combination therapies coupling gene therapy with immune checkpoint blockade to overcome tumor resistance mechanisms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Gene Therapy Market, by Vector Type

  • 8.1. Nonviral Vectors
    • 8.1.1. Lipid Nanoparticles
    • 8.1.2. Physical Methods
    • 8.1.3. Polymeric Nanoparticles
  • 8.2. Viral Vectors
    • 8.2.1. Adeno-Associated
    • 8.2.2. Adenoviral
    • 8.2.3. Lentiviral
    • 8.2.4. Retroviral

9. Cancer Gene Therapy Market, by Therapy Type

  • 9.1. Ex Vivo
  • 9.2. In Vivo

10. Cancer Gene Therapy Market, by Indication

  • 10.1. Hematological Cancers
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
    • 10.1.3. Myeloma
  • 10.2. Solid Tumors
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Prostate Cancer

11. Cancer Gene Therapy Market, by Stage

  • 11.1. Clinical Trials
    • 11.1.1. Phase I
    • 11.1.2. Phase II
    • 11.1.3. Phase III
  • 11.2. Commercial
  • 11.3. Preclinical

12. Cancer Gene Therapy Market, by End User

  • 12.1. Hospitals And Clinics
  • 12.2. Oncology Centers
  • 12.3. Research Laboratories

13. Cancer Gene Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Gene Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Gene Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Gilead Sciences, Inc.
    • 16.3.2. Novartis AG
    • 16.3.3. Bristol-Myers Squibb Company
    • 16.3.4. Amgen Inc.
    • 16.3.5. bluebird bio, Inc.
    • 16.3.6. Adaptimmune Therapeutics plc
    • 16.3.7. Cellectis S.A.
    • 16.3.8. uniQure N.V.
    • 16.3.9. Transgene SA
    • 16.3.10. Sorrento Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2